Ratings Keymed Biosciences Inc.

Equities

2162

KYG5252B1023

Delayed Hong Kong S.E. Other stock markets 01:09:05 30/04/2024 pm IST			5-day change	1st Jan Change
33.85 ^HKD	+1.04%		+4.80%	-31.06%

04:10am	Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA	MT
29/04	Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
KEYMED BIOSCIENCES INC.	-31.06%	1.18B	-
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B	B+
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B	B+
ARGENX SE	+1.63%	22.18B	B
BIONTECH SE	-16.67%	21.2B	B+
GENMAB A/S	-8.61%	18.31B	A-
WUXI APPTEC CO., LTD.	-38.74%	17.38B	A-
BEIGENE, LTD.	-13.21%	16.36B	B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B	C+
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes